The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Proton therapy – Present and future
Open accessAbstract
In principle, proton therapy offers a substantial clinical advantage over the conventional photon therapy. This is because of the unique depth-dose characteristics of protons, which can be exploited to achieve significant reductions in normal tissue doses proximal and distal to the target volume. These may, in turn, allow escalation of tumor doses, greater sparing of normal tissues, thus potentially improving local control and survival while at the same time reducing toxicity and improving quality of life. Protons, accelerated to therapeutic energies ranging from 70 to 250 MeV, typically with a cyclotron or a synchrotron, are transported to the treatment room where they enter the treatment head mounted on a rotating gantry. The initial thin beams of protons are spread laterally and longitudinally and shaped appropriately to deliver treatments. Spreading and shaping can be achieved by electro-mechanical means to treat the patients with “passively-scattered proton therapy (PSPT); or using magnetic scanning of thin “beamlets” of protons of a sequence of initial energies. The latter technique can be used to treat patients with optimized intensity modulated proton therapy (IMPT), the most powerful proton modality. Despite the high potential of proton therapy, the clinical evidence supporting the broad use of protons is mixed. It is generally acknowledged that proton therapy is safe, effective and recommended for many types of pediatric cancers, ocular melanomas, chordomas and chondrosarcomas. Although promising results have been and continue to be reported for many other types of cancers, they are based on small studies. Considering the high cost or establishing and operating proton therapy centers, questions have been raised about their cost effectiveness. General consensus is that there is a need to conduct randomized trials and/or collect outcomes data in multi-institutional registries to unequivocally demonstrate the advantage of protons. Treatment planning and plan evaluation of PSPT and IMPT requires special considerations compared to the processes used for photon treatment planning. The differences in techniques arise from the unique physical properties of protons but are also necessary because of the greater vulnerability of protons to uncertainties, especially from inter- and intra-fractional variations in anatomy. These factors must be considered in designing as well as evaluating treatment plans. In addition to anatomy variations, other sources of uncertainty in dose delivered to the patient include the approximations and assumptions of models used for computing dose distributions for planning of treatments. Furthermore, the relative biological effectiveness (RBE) of protons is simplistically assumed to have a constant value of 1.1. In reality, the RBE is variable and a complex function of energy of protons, dose per fraction, tissue and cell type, end point, etc. These uncertainties, approximations and current technological limitations of proton therapy may limit the achievement of the true potential of proton therapy. Ongoing research is aimed at better understanding the consequences of the various uncertainties on proton therapy, and reducing the uncertainties image-guidance, adaptive radiotherapy, further study of biological properties of protons, and the development of novel dose computation and optimization methods. However, residual uncertainties will remain in spite of the best efforts. To increase the resilience of dose distributions in the face of uncertainties and improve our confidence in dose distributions seen on treatment plans, robust optimization techniques are being developed and implemented. We assert that, with such research, proton therapy will be a commonly applied radiotherapy modality for most types of solid cancers in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Prescribing, recording, and reporting photon beam therapy
Icru (1993) · Medical Entomology and Zoology · Cited by 1,996
Radiological Use of Fast Protons
Wilson, R. R. (1946) · Radiology · doi:10.1148/47.5.487 · Cited by 1,403
Relative biological effectiveness (RBE) values for proton beam therapy
Paganetti, H., Niemierko, A., Ancukiewicz, M., Gerweck, L. E., Goitein, M., Loeffler, J. S., & Suit, H. D. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02754-2 · Cited by 1,364
Paganetti, H. (2014) · Physics in Medicine and Biology · doi:10.1088/0031-9155/59/22/r419 · Cited by 915
Zietman, A. L., Bae, K., Slater, J. D., Shipley, W. U., Efstathiou, J. A., Coen, J. J., Bush, D. A., Lunt, M., Spiegel, D. Y., Skowronski, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8475 · Cited by 735
Goldin, G. H. (2012) · JAMA · doi:10.1001/jama.2012.460 · Cited by 445
Shipley, W. U., Verhey, L. J., Munzenrider, J. E., Suit, H. D., Urie, M. M., McManus, P. L., Young, R. H., Shipley, J. W., Zietman, A. L., Biggs, P. J., et al. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00063-5 · Cited by 407
Goitein, M., Abrams, M., Rowell, D., Pollari, H., & Wiles, J. (1983) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(83)90003-2 · Cited by 392
Robust optimization of intensity modulated proton therapy: Robust optimization of IMPT
Liu, W., Zhang, X., Li, Y., & Mohan, R. (2012) · Medical Physics · doi:10.1118/1.3679340 · Cited by 354
Self-citationIncidence of Second Malignancies Among Patients Treated With Proton Versus Photon Radiation
Chung, C. S., Yock, T. I., Nelson, K., Xu, Y., Keating, N. L., & Tarbell, N. J. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.04.030 · Cited by 306
Ares, C., Hug, E. B., Lomax, A. J., Bolsi, A., Timmermann, B., Rutz, H. P., Schuller, J. C., Pedroni, E., & Goitein, G. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.12.055 · Cited by 279
Proton therapy for prostate cancer: the initial Loma Linda University experience
Slater, J. D., Rossi, C. J., Yonemoto, L. T., Bush, D. A., Jabola, B. R., Levy, R. P., Grove, R. I., Preston, W., & Slater, J. M. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.10.011 · Cited by 276
Patel, S. H., Wang, Z., Wong, W. W., Murad, M. H., Buckey, C. R., Mohammed, K., Alahdab, F., Altayar, O., Nabhan, M., Schild, S. E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70268-2 · Cited by 262
A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy
Lomax, A. J., Bortfeld, T., Goitein, G., Debus, J., Dykstra, C., Tercier, P.-A., Coucke, P. A., & Mirimanoff, R. O. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00036-5 · Cited by 245
Paganetti, H. (2002) · Physics in Medicine and Biology · doi:10.1088/0031-9155/47/5/305 · Cited by 237
An evidence based review of proton beam therapy: The report of ASTRO’s emerging technology committee
Allen, A. M., Pawlicki, T., Dong, L., Fourkal, E., Buyyounouski, M., Cengel, K., Plastaras, J., Bucci, M. K., Yock, T. I., Bonilla, L., et al. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.02.001 · Cited by 236
Brainstem tolerance to conformal radiotherapy of skull base tumors
Debus, J., Hug, E. B., Liebsch, N. J., O'Farrel, D., Finkelstein, D., Efird, J., & Munzenrider, J. E. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00364-7 · Cited by 208
Proton Therapy in Clinical Practice: Current Clinical Evidence
Brada, M., Pijls-Johannesma, M., & De Ruysscher, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.0131 · Cited by 205
Compensating for heterogeneities in proton radiation therapy
Urie, M., Goitein, M., & Wagner, M. (1984) · Physics in Medicine and Biology · doi:10.1088/0031-9155/29/5/008 · Cited by 183
Chang, J. Y., Komaki, R., Lu, C., Wen, H. Y., Allen, P. K., Tsao, A., Gillin, M., Mohan, R., & Cox, J. D. (2011) · Cancer · doi:10.1002/cncr.26080 · Cited by 180
Self-citationSethi, R. V., Shih, H. A., Yeap, B. Y., Mouw, K. W., Petersen, R., Kim, D. Y., Munzenrider, J. E., Grabowski, E., Rodriguez‐Galindo, C., Yock, T. I., et al. (2014) · Cancer · doi:10.1002/cncr.28387 · Cited by 174
Bishop, A. J., Greenfield, B., Mahajan, A., Paulino, A. C., Okcu, M. F., Allen, P. K., Chintagumpala, M., Kahalley, L. S., McAleer, M. F., McGovern, S. L., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.05.051 · Cited by 168
Self-citationWenkel, E., Thornton, A. F., Finkelstein, D., Adams, J., Lyons, S., De La Monte, S., Ojeman, R. G., & Munzenrider, J. E. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01411-5 · Cited by 159
Proton therapy for low‐grade gliomas: Results from a prospective trial
Shih, H. A., Sherman, J. C., Nachtigall, L. B., Colvin, M. K., Fullerton, B. C., Daartz, J., Winrich, B. K., Batchelor, T. T., Thornton, L. T., Mancuso, S. M., et al. (2015) · Cancer · doi:10.1002/cncr.29237 · Cited by 154
Smith, A. R. (2009) · Medical Physics · doi:10.1118/1.3058485 · Cited by 151
The Clinical Potential of Intensity Modulated Proton Therapy
Lomax, A., Pedroni, E. S., Rutz, H. P., et al. (2004) · Zeitschrift für Medizinische Physik · doi:10.1078/0939-3889-00217 · Cited by 151
Degradation of the Bragg peak due to inhomogeneities
Urie, M. M., Goitein, M., Holley, W. R., & Chen, G. T. Y. (1986) · Physics in Medicine and Biology · doi:10.1088/0031-9155/31/1/001 · Cited by 123
Fitzek, M. M., Thornton, A. F., Harsh, G. R., et al. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01589-9 · Cited by 56
Cited by
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Ferroptosis, radiotherapy, and combination therapeutic strategies
Lei, G., Mao, C., Yan, Y., Zhuang, L., & Gan, B. (2021) · Protein & Cell · doi:10.1007/s13238-021-00841-y · Cited by 504
Kahalley, L. S., Peterson, R., Ris, M. D., Janzen, L., Okcu, M. F., Grosshans, D. R., Ramaswamy, V., Paulino, A. C., Hodgson, D., Mahajan, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01706 · Cited by 256
Self-citationEnhancing Proton Therapy Efficacy Through Nanoparticle-Mediated Radiosensitization
Ma, J., Shen, H., & Mi, Z. (2024) · Cells · doi:10.3390/cells13221841 · Cited by 23
In vivo validation of the BIANCA biophysical model: benchmarking against rat spinal cord RBE data
Carante, M. P., Aricò, G., Ferrari, A., Karger, C. P., Kozlowska, W., Mairani, A., Sala, P., & Ballarini, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113973 · Cited by 21
Metadata
- Authors
- Mohan, R., & Grosshans, D.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 109
- Pages
- 26-44
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2557556302
- Cited by
- 608
- References
- 29
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.